127.81
price up icon0.68%   0.8899
 
loading

Biogen Inc (BIIB) 最新ニュース

pulisher
Jun 18, 2025

Missouri Trust & Investment Co Has $866,000 Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Grimes & Company Inc. Purchases 33,721 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Fifth Third Bancorp Has $751,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen bids to extend use of Skyclarys to younger patients - pharmaphorum

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Dips on Its Part in BRAVE Study - Baystreet.ca

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxol - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen initiates phase 3 trial of omaveloxolone for children with FA - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen

Jun 18, 2025
pulisher
Jun 18, 2025

How the Neuroprotection Therapeutics Market Will Evolve by 2032 - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa KirinResearchAndMarkets.com - Bluefield Daily Telegraph

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen patents new HTT splicing modulators - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bill Nye joins fireside chat supporting Biogen’s Cannes Lion-winning work - Medical Marketing and Media

Jun 17, 2025
pulisher
Jun 16, 2025

NorthCrest Asset Manangement LLC Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire

Jun 16, 2025
pulisher
Jun 15, 2025

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

Biogen's (BIIB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals

Jun 13, 2025
pulisher
Jun 13, 2025

Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum

Jun 13, 2025
pulisher
Jun 12, 2025

Biogen Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 ResultsBiogen (NASDAQ:BIIB) - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen: positive Phase 3 data in lupus - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus D - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Is Biogen Stock Underperforming The S&P 500? - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Is Biogen Stock Underperforming the S&P 500? - The Globe and Mail

Jun 12, 2025
drug_manufacturers_general SNY
$48.28
price down icon 0.13%
$107.07
price up icon 2.01%
drug_manufacturers_general PFE
$24.32
price up icon 0.35%
$278.56
price down icon 0.88%
drug_manufacturers_general MRK
$79.05
price down icon 0.70%
drug_manufacturers_general NVS
$120.06
price down icon 0.13%
大文字化:     |  ボリューム (24 時間):